Longitudinal analyses of healthcare resource utilization and costs among patients with obstructive hypertrophic cardiomyopathy.
Saved in:
| Title: | Longitudinal analyses of healthcare resource utilization and costs among patients with obstructive hypertrophic cardiomyopathy. |
|---|---|
| Authors: | Reza N; Division of Cardiovascular Medicine, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA., Butzner M; Cytokinetics, Inc, South San Francisco, CA, USA., Batra K; Optum, Eden Prairie, MN, USA., Amos Q; Optum, Eden Prairie, MN, USA., Buikema A; Optum, Eden Prairie, MN, USA., Shreay S; Cytokinetics, Inc, South San Francisco, CA, USA., Owens A; Division of Cardiovascular Medicine, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. |
| Source: | Journal of medical economics [J Med Econ] 2025 Dec; Vol. 28 (1), pp. 1979-1988. Date of Electronic Publication: 2025 Nov 16. |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 9892255 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1941-837X (Electronic) Linking ISSN: 13696998 NLM ISO Abbreviation: J Med Econ Subsets: MEDLINE |
| Imprint Name(s): | Publication: 2015- : Abingdon, Oxford : Taylor & Francis Original Publication: Richmond, Surrey : Brookwood Medical, 1998- |
| MeSH Terms: | Cardiomyopathy, Hypertrophic*/economics , Cardiomyopathy, Hypertrophic*/therapy , Patient Acceptance of Health Care*/statistics & numerical data , Health Expenditures*/statistics & numerical data , Health Resources*/statistics & numerical data , Health Resources*/economics, Humans ; Male ; Female ; Retrospective Studies ; Middle Aged ; Adult ; Aged ; Insurance Claim Review ; Longitudinal Studies ; Hospitalization/economics ; Hospitalization/statistics & numerical data ; Emergency Service, Hospital/statistics & numerical data ; Emergency Service, Hospital/economics ; Ambulatory Care/statistics & numerical data ; Ambulatory Care/economics ; Length of Stay/statistics & numerical data ; Length of Stay/economics |
| Abstract: | Aims: Obstructive hypertrophic cardiomyopathy (oHCM) is associated with substantial disease burden, healthcare resource utilization (HCRU), and healthcare costs. This study assessed HCRU and healthcare costs among patients with oHCM treated in real-world settings over 5 years of follow-up. Methods: This retrospective cohort study used the Optum database (January 2013-December 2021) and included patients aged ≥18 years with ≥2 claims for oHCM and continuous health plan enrollment for ≥6 months pre-initial and post-initial oHCM claim (index date). Patients with ≥5 years of follow-up data were analyzed. All-cause and HCM-related HCRU (ambulatory visits [physician office visits and outpatient visits], emergency room [ER] visits, hospital admissions, length of stay [LOS], and pharmacy use) and healthcare costs were assessed in US dollars. Results: In total, 5,129 patients with oHCM were identified: 5,056 (98.6%) had an all-cause ambulatory visit and 4,669 (91.0%) had an HCM-related visit. 4,079 (79.5%) had an all-cause ER visit, and 1,499 (29.2%) an HCM-related ER visit. 2,949 (57.5%) reported an all-cause admission, and 2,232 (43.5%) an HCM-related admission. The mean (SD) per-person count of all-cause ambulatory visits was 101.0 (90.7) and 15.3 (18.7) for HCM-related ambulatory visits. Mean (SD) all-cause admissions per patient were 1.8 (3.8), and 0.9 (1.6) were HCM related. Mean (SD) all-cause LOS was 18.0 (54.7) days, and HCM-related LOS was 10.0 (39.6) days. Mean (SD) all-cause healthcare cost per patient was $181,968 (241,608), of which $67,531 (114,705) was HCM related. Hospital admissions were the largest proportion of medical costs: all-cause admissions cost $71,001 (149,533) during follow-up, of which $44,781 (99,431) was HCM-related. Limitations: Analyses were unadjusted for covariates or confounding factors. Conclusion: Patients with oHCM experience substantial HCRU and costs over 5 years of follow-up. These results indicate a need for new treatment options which could decrease HCRU and improve patient outcomes. |
| References: | JACC Heart Fail. 2022 Aug;10(8):571-580. (PMID: 35902161) PLoS One. 2018 May 3;13(5):e0196612. (PMID: 29723226) Am J Cardiol. 2021 Nov 15;159:107-112. (PMID: 34503822) Glob Heart. 2023 Aug 04;18(1):40. (PMID: 37547171) Cardiol Ther. 2022 Dec;11(4):491-507. (PMID: 36243823) Am Heart J Plus. 2022 Jan 31;13:100089. (PMID: 38560082) Circulation. 2024 Jun 4;149(23):e1239-e1311. (PMID: 38718139) Mult Scler Relat Disord. 2023 Mar;71:104512. (PMID: 36716576) Cardiol Ther. 2022 Jun;11(2):249-267. (PMID: 35230625) Circulation. 2024 Oct 22;150(17):1377-1390. (PMID: 39355918) Patient Prefer Adherence. 2023 May 03;17:1181-1196. (PMID: 37163154) Am J Cardiol. 2023 Apr 1;192:16-23. (PMID: 36709525) Am J Cardiol. 2022 Jul 1;174:120-125. (PMID: 35473784) J Clin Pharmacol. 2022 Dec;62 Suppl 2:S38-S55. (PMID: 36461748) Am J Cardiol. 2016 May 15;117(10):1651-1654. (PMID: 27006153) J Med Econ. 2021 Jan-Dec;24(1):1115-1123. (PMID: 34493144) |
| Grant Information: | K23 HL166961 United States HL NHLBI NIH HHS |
| Contributed Indexing: | Keywords: I13; I14; Obstructive hypertrophic cardiomyopathy; economic burden; economic study; healthcare costs; healthcare resource utilization; real-world population Local Abstract: [plain-language-summary] Previous studies have looked at healthcare needs (or healthcare resource use; HCRU) and costs of treating people with obstructive hypertrophic cardiomyopathy (oHCM). But those studies only looked at HCRU and costs over 3 years or less. In this study, we looked at healthcare needs and costs over 5 years using data from healthcare claims in the United States. We found that people with oHCM had high HCRU, with 9 out of 10 having a healthcare visit related to their disease, and 4 out of 10 a hospital admission related to their disease. People with oHCM also had high healthcare costs, with average healthcare costs related to their disease of $67,531 over the 5 year study; which is over $13,500 per person each year. These findings show that there is a need to reduce HCRU for people with oHCM, and that this would also reduce their healthcare costs. New treatments for people with oHCM could decrease HCRU while also improving people’s health. |
| Entry Date(s): | Date Created: 20251116 Date Completed: 20251116 Latest Revision: 20251202 |
| Update Code: | 20251202 |
| PubMed Central ID: | PMC12643539 |
| DOI: | 10.1080/13696998.2025.2584888 |
| PMID: | 41241831 |
| Database: | MEDLINE |
Nájsť tento článok vo Web of Science | Abstract: | Aims: Obstructive hypertrophic cardiomyopathy (oHCM) is associated with substantial disease burden, healthcare resource utilization (HCRU), and healthcare costs. This study assessed HCRU and healthcare costs among patients with oHCM treated in real-world settings over 5 years of follow-up.<br />Methods: This retrospective cohort study used the Optum database (January 2013-December 2021) and included patients aged ≥18 years with ≥2 claims for oHCM and continuous health plan enrollment for ≥6 months pre-initial and post-initial oHCM claim (index date). Patients with ≥5 years of follow-up data were analyzed. All-cause and HCM-related HCRU (ambulatory visits [physician office visits and outpatient visits], emergency room [ER] visits, hospital admissions, length of stay [LOS], and pharmacy use) and healthcare costs were assessed in US dollars.<br />Results: In total, 5,129 patients with oHCM were identified: 5,056 (98.6%) had an all-cause ambulatory visit and 4,669 (91.0%) had an HCM-related visit. 4,079 (79.5%) had an all-cause ER visit, and 1,499 (29.2%) an HCM-related ER visit. 2,949 (57.5%) reported an all-cause admission, and 2,232 (43.5%) an HCM-related admission. The mean (SD) per-person count of all-cause ambulatory visits was 101.0 (90.7) and 15.3 (18.7) for HCM-related ambulatory visits. Mean (SD) all-cause admissions per patient were 1.8 (3.8), and 0.9 (1.6) were HCM related. Mean (SD) all-cause LOS was 18.0 (54.7) days, and HCM-related LOS was 10.0 (39.6) days. Mean (SD) all-cause healthcare cost per patient was $181,968 (241,608), of which $67,531 (114,705) was HCM related. Hospital admissions were the largest proportion of medical costs: all-cause admissions cost $71,001 (149,533) during follow-up, of which $44,781 (99,431) was HCM-related.<br />Limitations: Analyses were unadjusted for covariates or confounding factors.<br />Conclusion: Patients with oHCM experience substantial HCRU and costs over 5 years of follow-up. These results indicate a need for new treatment options which could decrease HCRU and improve patient outcomes. |
|---|---|
| ISSN: | 1941-837X |
| DOI: | 10.1080/13696998.2025.2584888 |